NEWS AND UPDATES
January 2026
AI-Designed Drug Reach
The landscape of Drug Development has reached a definitive turning point as the first therapeutic agent entively identified through artificial intelligence completes its Phase 3 trials with significant sucess.
Ultra-Long-Acting Biologics for Asthma
For patients battling severe eosinophilic asthma, the approval of a
biological that requires only two doses per year replacing monthly clinical visits with a long-acting, sustainable alternative is a breakthrough.
Advancing Rare Pediatric Gene Therapies
Utilizing advanced lentiviral vector technology, a new gene therapy is
now able to re-engineer a patient’s own hematopoietic stem cells to
restore immune function and platelet production.
COMPANY EVENTS
Fostering a culture of innovation and beloging through team-building
professional development, and celebrations of our collective success
QUARTER 2
BUSINESS REVIEW
Our recent business review brought together leadership and key stakeholders to analyze our 2025 performance and solidify our strategic roadmap for the coming year.
GENERAL ASSEMBLY
2025
Analyzing our achievements and addressing upcoming industry challenges, we have established a clear, data-driven path forward to maintain our leadership in pharmaceutical innovation.
BACK TO SCHOOL
YEAR-END PARTY
From vintage lunchboxes to varsity jackets, our team traded professional attire for schoolyard
style at this year's
'Back to School themed Christmas Party.
FEATURED PRODUCTS
